



Clinical trial results:

A phase 2a proof of concept, randomised, double-blind, placebo-controlled study to evaluate the safety/tolerability and efficacy of 4 subcutaneous injections of namilumab (150 mg) given over 10 weeks in subjects with moderate-to-severely active axial spondyloarthritis including those previously exposed to anti-TNF therapy (NAMASTE study)

Summary

EudraCT number	2018-000176-15
Trial protocol	GB
Global end of trial date	04 February 2020

Results information

Result version number	v1 (current)
This version publication date	19 February 2021
First version publication date	19 February 2021

Trial information

Trial identification

Sponsor protocol code	IZN-101
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Izana Bioscience Ltd
Sponsor organisation address	11-12 St. James's Square, Suite 1, 3rd Floor, London, United Kingdom, SW1Y 4LB
Public contact	Simon Lowry, MD, Head of Clinical Development, Roivant Sciences, Inc., on behalf of Izana Bioscience Limited, 1 (973) 309-1394, simon.lowry@roivant.com
Scientific contact	Simon Lowry, MD, Head of Clinical Development, Roivant Sciences, Inc., on behalf of Izana Bioscience Limited, 1 (973) 309-1394, simon.lowry@roivant.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 May 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 February 2020
Global end of trial reached?	Yes
Global end of trial date	04 February 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy of namilumab 150 mg subcutaneous (sc), given on weeks 0, 2, 6 and 10 in subjects with axSpA. The study consisted of a maximum four-week Screening period, followed by a 12-week double-blind treatment evaluation period, followed by a 16-week safety follow-up period.

Protection of trial subjects:

Safety was evaluated based on adverse events (AEs), clinical laboratory tests, vital sign measurements, physical examinations, ECGs (screening only), concomitant medication review, injection-site reactions, allergic reactions, infections, and tuberculosis (TB) evaluations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	10 July 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 42
Worldwide total number of subjects	42
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	41

From 65 to 84 years	1
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

42 were randomised (36 subjects to treatment and 6 subjects to placebo)

Pre-assignment

Screening details:

42 were randomised (36 subjects to treatment and 6 subjects to placebo)

Period 1

Period 1 title	Randomised (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	namilumab 150 mg
------------------	------------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	namilumab (150 mg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection, Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

4 subcutaneous injections of namilumab (150 mg) given over 10 weeks

Arm title	Placebo
------------------	---------

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

4 subcutaneous injections given over 10 weeks

Number of subjects in period 1	namilumab 150 mg	Placebo
Started	36	6
Completed	36	6

Baseline characteristics

Reporting groups

Reporting group title	namilumab 150 mg
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Reporting group values	namilumab 150 mg	Placebo	Total
Number of subjects	36	6	42
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	35	6	41
From 65-84 years	1	0	1
85 years and over	0	0	0
Age continuous Units: years			
median	39	38	-
standard deviation	± 13.93	± 9.2	-
Gender categorical Units: Subjects			
Female	15	2	17
Male	21	4	25
Duration of disease Units: Subjects			
More than 2 years	36	6	42
Prior Use of Anti-TNF Treatment Units: Subjects			
Yes	36	6	42

Subject analysis sets

Subject analysis set title	Treatment
Subject analysis set type	Full analysis
Subject analysis set description: The FAS contains all subjects in the RND who received at least one dose of study drug.	
Subject analysis set title	Placebo
Subject analysis set type	Full analysis
Subject analysis set description: The FAS contains all subjects in the RND who received at least one dose of study drug.	

Reporting group values	Treatment	Placebo	
Number of subjects	36	6	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	35	6	
From 65-84 years	1	0	
85 years and over	0	0	
Age continuous			
Units: years			
median	39	38	
standard deviation	± 13.93	± 9.2	
Gender categorical			
Units: Subjects			
Female	15	2	
Male	21	4	
Duration of disease			
Units: Subjects			
More than 2 years	20	2	
Prior Use of Anti-TNF Treatment			
Units: Subjects			
Yes	6	1	

End points

End points reporting groups

Reporting group title	namilumab 150 mg
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	
Subject analysis set title	Treatment
Subject analysis set type	Full analysis
Subject analysis set description: The FAS contains all subjects in the RND who received at least one dose of study drug.	
Subject analysis set title	Placebo
Subject analysis set type	Full analysis
Subject analysis set description: The FAS contains all subjects in the RND who received at least one dose of study drug.	

Primary: ASAS20 Clinical Response at week 12

End point title	ASAS20 Clinical Response at week 12
End point description: The primary endpoint was the proportion of subjects who achieved an ASAS20 clinical response at Week 12.	
End point type	Primary
End point timeframe: Week 12	

End point values	namilumab 150 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	36	6		
Units: percent				
number (not applicable)	14	3		

Statistical analyses

Statistical analysis title	Bayesian analysis
Comparison groups	namilumab 150 mg v Placebo
Number of subjects included in analysis	42
Analysis specification	Pre-specified
Analysis type	other
P-value	> 0.927
Method	Bayesian
Parameter estimate	beta prior

Secondary: Proportion of subjects who achieved Assessment in Ankylosing Spondylitis with 40% improvement (ASAS40), Week 12

End point title	Proportion of subjects who achieved Assessment in Ankylosing Spondylitis with 40% improvement (ASAS40), Week 12
End point description: Proportion of subjects who achieved Assessment in Ankylosing Spondylitis with 40% improvement (ASAS40) response at Week 12	
End point type	Secondary
End point timeframe: 12 weeks	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects Who Achieved ASAS20 Clinical Response at Week 6

End point title	Proportion of Subjects Who Achieved ASAS20 Clinical Response at Week 6
End point description: Proportion of Subjects Who Achieved ASAS20 Clinical Response at Week 6	
End point type	Secondary
End point timeframe: Week 6	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportions of Subjects Who Achieved Clinically Important ASDAS-CRP Score at Week 6

End point title	Proportions of Subjects Who Achieved Clinically Important ASDAS-CRP Score at Week 6
-----------------	-------------------------------------------------------------------------------------

End point description:	
Proportions of Subjects Who Achieved Clinically Important ASDAS-CRP Score at Week 6	
End point type	Secondary
End point timeframe:	
Week 6	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportions of Subjects Who Achieved Clinically Important ASDAS-CRP Score at Week 12

End point title	Proportions of Subjects Who Achieved Clinically Important ASDAS-CRP Score at Week 12
End point description:	
Proportions of Subjects Who Achieved Clinically Important ASDAS-CRP Score at Week 12	
End point type	Secondary
End point timeframe:	
12 weeks	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

28 weeks

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23
--------------------	----

Reporting groups

Reporting group title	placebo
-----------------------	---------

Reporting group description:

Subjects were given four sc injections of placebo over 10 weeks and followed up for 28 weeks

Reporting group title	Treatment
-----------------------	-----------

Reporting group description:

All subjects that received at least one dose subcutaneous of namilumab 150 mg

Serious adverse events	placebo	Treatment	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 6 (0.00%)	1 / 36 (2.78%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Injury, poisoning and procedural complications			
Road traffic accident			
subjects affected / exposed	0 / 6 (0.00%)	1 / 36 (2.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Duodenitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 36 (2.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	placebo	Treatment	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 6 (83.33%)	31 / 36 (86.11%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 6 (0.00%)	2 / 36 (5.56%)	
occurrences (all)	0	2	
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	1 / 6 (16.67%)	1 / 36 (2.78%)	
occurrences (all)	1	1	
Reproductive system and breast disorders			
Polymenorrhoea			
subjects affected / exposed	1 / 6 (16.67%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 6 (0.00%)	3 / 36 (8.33%)	
occurrences (all)	0	3	
Dyspnoea			
subjects affected / exposed	0 / 6 (0.00%)	3 / 36 (8.33%)	
occurrences (all)	0	3	
Pleuritic pain			
subjects affected / exposed	1 / 6 (16.67%)	1 / 36 (2.78%)	
occurrences (all)	1	1	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 6 (0.00%)	2 / 36 (5.56%)	
occurrences (all)	0	2	
Investigations			
Protein urine present			
subjects affected / exposed	1 / 6 (16.67%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Injury, poisoning and procedural complications			
Limb injury			

subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 36 (0.00%) 0	
Nervous system disorders Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	3 / 36 (8.33%) 3	
Blood and lymphatic system disorders Macrocytosis subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 36 (0.00%) 0	
Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all) Gastritis subjects affected / exposed occurrences (all) Frequent bowel movements subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 1 / 6 (16.67%) 1	7 / 36 (19.44%) 7 3 / 36 (8.33%) 3 3 / 36 (8.33%) 3 2 / 36 (5.56%) 2 0 / 36 (0.00%) 0	
Skin and subcutaneous tissue disorders Urticaria subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 36 (0.00%) 0	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) Pain in extremity	0 / 6 (0.00%) 0	2 / 36 (5.56%) 2	

subjects affected / exposed	1 / 6 (16.67%)	1 / 36 (2.78%)	
occurrences (all)	1	1	
Neck pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Osteopenia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	9 / 36 (25.00%)	
occurrences (all)	0	9	
Lower respiratory tract infection			
subjects affected / exposed	1 / 6 (16.67%)	2 / 36 (5.56%)	
occurrences (all)	1	2	
Urinary tract infection			
subjects affected / exposed	1 / 6 (16.67%)	2 / 36 (5.56%)	
occurrences (all)	1	2	
Upper respiratory tract infection			
subjects affected / exposed	1 / 6 (16.67%)	1 / 36 (2.78%)	
occurrences (all)	1	1	
Infected cyst			
subjects affected / exposed	1 / 6 (16.67%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Otitis externa			
subjects affected / exposed	1 / 6 (16.67%)	0 / 36 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported